Claim denials are rising due to data inaccuracies, staffing shortages, and outdated technology, with 41% of providers experiencing denial rates of 10% or higher. Economic pressures and declining ...

Tory M. Wolff, MBA, discusses his study showing that frequent routine primary care visits may lower costs for higher-risk commercially insured adults. In this conversation, Wolff explores the ...

Prior authorizations can affect both health system operations and worsen physician burnout. What does existing research show about how prior authorization requirements affect health system operations?

Oncology pharmacists now work alongside providers to improve efficiency, patient education, and treatment outcomes, according to Scott Soefje, PharmD, MBA, BCOP.

Hope Krebill of the Masonic Cancer Alliance at the University of Kansas Medical Center outlines patient navigation models that improve outcomes and reduce missed appointments.

Experts at European Respiratory Society (ERS) Congress 2025 highlight the critical link between reduced lung function and increased cardiovascular disease risk, urging early intervention and awareness ...

Planetary health links human well-being with ecosystem health, emphasizing biodiversity loss as a driver of respiratory conditions like asthma and allergies. Healthcare contributes significantly to ...

Pfizer's agreement includes a 3-year grace period to avoid tariffs on drugs manufactured outside the US, with significant discounts on select medications. The Trump administration advances the Most ...

Experts at the European Respiratory Society (ERS) Congress 2025 highlight threats to scientific integrity from misinformation, political interference, and predatory publishing in health research.

The FDA today approved remibrutinib (Rhapsido; Novartis), a highly selective Bruton tyrosine kinase inhibitor (BTKi), for the treatment of chronic spontaneous urticaria (CSU) in patients who remain ...

The findings support a new Human Immune Dysregulation Evaluation Framework (Hi-DEF), according to researchers, which categorizes patients into 4 immune states: myeloid dysregulation, lymphoid ...

Emma Guttman-Yassky, MD, PhD, discusses the long-term efficacy of deuruxolitinib in alopecia areata.